BR112015022917A2 - peptidoglicanos sintéticos componentes da matriz extracelular - Google Patents

peptidoglicanos sintéticos componentes da matriz extracelular

Info

Publication number
BR112015022917A2
BR112015022917A2 BR112015022917A BR112015022917A BR112015022917A2 BR 112015022917 A2 BR112015022917 A2 BR 112015022917A2 BR 112015022917 A BR112015022917 A BR 112015022917A BR 112015022917 A BR112015022917 A BR 112015022917A BR 112015022917 A2 BR112015022917 A2 BR 112015022917A2
Authority
BR
Brazil
Prior art keywords
extracellular matrix
matrix components
synthetic peptidoglycans
synthetic
peptidoglycans
Prior art date
Application number
BR112015022917A
Other languages
English (en)
Inventor
Pantch Alyssa
Eric Paderi John
Allison Stuart Katherine
Marie Vazquez-Portalatin Nelda
Sharma Shaili
Original Assignee
Symic Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symic Biomedical Inc filed Critical Symic Biomedical Inc
Publication of BR112015022917A2 publication Critical patent/BR112015022917A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

resumo patente de invenção: "peptidoglicanos sintéticos componentes da matriz extracelular". esta invenção provê peptidoglicanos sintéticos componentes de matrizes extracelulares compreendendo um ou mais peptídeos sintéticos conjugados a um glicano e métodos para sua utilização.
BR112015022917A 2013-03-15 2014-03-14 peptidoglicanos sintéticos componentes da matriz extracelular BR112015022917A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798916P 2013-03-15 2013-03-15
PCT/US2014/029596 WO2014144969A1 (en) 2013-03-15 2014-03-14 Extracellular matrix-binding synthetic peptidoglycans

Publications (1)

Publication Number Publication Date
BR112015022917A2 true BR112015022917A2 (pt) 2017-07-18

Family

ID=51537842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022917A BR112015022917A2 (pt) 2013-03-15 2014-03-14 peptidoglicanos sintéticos componentes da matriz extracelular

Country Status (14)

Country Link
US (3) US9200039B2 (pt)
EP (1) EP2970509B1 (pt)
JP (1) JP6603650B2 (pt)
KR (1) KR20150130419A (pt)
AU (1) AU2014233537A1 (pt)
BR (1) BR112015022917A2 (pt)
CA (1) CA2903450A1 (pt)
EA (1) EA201591454A1 (pt)
HK (1) HK1220217A1 (pt)
IL (1) IL241054A0 (pt)
MX (1) MX2015012608A (pt)
SG (1) SG11201506966RA (pt)
WO (1) WO2014144969A1 (pt)
ZA (1) ZA201506391B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
US9217016B2 (en) 2011-05-24 2015-12-22 Symic Ip, Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2956137A1 (en) 2014-05-12 2015-11-19 Alyssa Panitch Selectin and icam/vcam peptide ligand conjugates
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
JP6693728B2 (ja) * 2014-11-14 2020-05-13 興和株式会社 新規な機能性ペプチド
US10463769B2 (en) 2014-12-19 2019-11-05 Northwestern University Thromboresistant-anticoagulant extracellular matrix
WO2016161333A2 (en) * 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
US20160331841A1 (en) * 2015-04-17 2016-11-17 Symic Ip, Llc Bioconjugates and uses thereof
US10463745B2 (en) * 2015-05-12 2019-11-05 Northwestern University Materials for tissue regeneration
CA3035659C (en) * 2016-09-16 2022-09-06 Glycologix, Llc Sulfated glycosaminoglycan biomaterials as proteoglycan mimics
WO2019010485A1 (en) * 2017-07-07 2019-01-10 Symic Ip, Llc TREATMENT OF FIBROSIS
CN111050778A (zh) * 2017-07-07 2020-04-21 斯米克Ip有限公司 具有化学修饰的骨架的生物缀合物
WO2019010484A2 (en) 2017-07-07 2019-01-10 Symic Ip, Llc SYNTHETIC BIOCONJUGATES
WO2022256568A1 (en) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors
WO2024080183A1 (ja) * 2022-10-14 2024-04-18 国立大学法人東海国立大学機構 糖鎖複合体、薬物担体、及びドラッグデリバリーシステム

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683298A (en) 1985-01-10 1987-07-28 British Columbia Research Council Process for the preparation of aminated polysaccharide derivatives
US5547936A (en) 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
ES2084688T3 (es) 1988-12-20 1996-05-16 Jolla Cancer Res Found Conjugados de polipeptido-polimero para el tratamiento de heridas.
US5693625A (en) 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
EP0567575B1 (en) 1991-01-14 1999-10-13 New York University Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
JP2901787B2 (ja) 1991-07-15 1999-06-07 日本メジフィジックス株式会社 核磁気共鳴造影剤
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
DK2111876T3 (da) 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Tværbundne polymerpræparater og fremgangsmåder til anvendelse deraf
CA2299687C (en) 1997-08-04 2009-10-27 Bio Syntech Ltd. Temperature-controlled ph-dependant formation of ionic polysaccharide gels
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
EP1854885B9 (en) 1997-11-21 2011-03-16 Merck Serono Biodevelopment Chlamydia pneumoniae outer membrane polypeptide, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7691829B2 (en) 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
JP3103531B2 (ja) 1998-09-30 2000-10-30 延也 柳内 ヒト尿由来細胞接着糖蛋白質及びその製造方法
US6822071B1 (en) 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20110214206A1 (en) 1999-05-06 2011-09-01 La Rosa Thomas J Nucleic acid molecules and other molecules associated with plants
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
FR2794976B1 (fr) 1999-06-16 2004-05-07 Solutions Compositions pharmaceutiques a action cicatrisante ou anti-complementaire comprenant un derive de dextrane
JP4786095B2 (ja) 1999-09-15 2011-10-05 ユークリッド システムズ コーポレイション 角膜矯正レンズ装着中または装着後の角膜組織を安定化するための組成物
FR2799465B1 (fr) 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
AU1979201A (en) 1999-12-09 2001-06-18 Bio Syntech Canada Inc Mineral-polymer hybrid composition
US20030158302A1 (en) 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
AU2001288392A1 (en) 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
WO2002018423A1 (en) 2000-08-31 2002-03-07 University Of Delaware Bioactive peptide for cell adhesion
AU2002211517A1 (en) 2000-10-04 2002-04-15 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
EP1335687B1 (en) 2000-11-15 2007-01-10 Bio Syntech Canada Inc. Method for restoring a damaged or degenerated intervertebral disc
AU2002359236A1 (en) 2001-07-13 2003-04-14 Advanced Research And Technology Institute Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
EP1423133B1 (en) 2001-08-15 2009-01-14 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
ATE494309T1 (de) 2001-11-15 2011-01-15 Biosyntech Canada Inc Zusammensetzung und verfahren um chitosan unter neutralen bedingungen homogen zu modifizieren oder vernetzen
US20090100536A1 (en) 2001-12-04 2009-04-16 Monsanto Company Transgenic plants with enhanced agronomic traits
US20090158452A1 (en) 2001-12-04 2009-06-18 Johnson Richard G Transgenic plants with enhanced agronomic traits
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003075848A2 (en) 2002-03-08 2003-09-18 Zymogenetics, Inc. Inhibitors for use in hemostasis
US7666852B2 (en) 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
JP2005185101A (ja) 2002-05-30 2005-07-14 National Institute Of Agrobiological Sciences 植物の全長ｃＤＮＡおよびその利用
US8673333B2 (en) 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
US7862831B2 (en) 2002-10-09 2011-01-04 Synthasome, Inc. Method and material for enhanced tissue-biomaterial integration
US20090183270A1 (en) 2002-10-02 2009-07-16 Adams Thomas R Transgenic plants with enhanced agronomic traits
EP1570045A4 (en) 2002-10-04 2007-09-05 Univ Minnesota NUCLEIC ACID AND POLYPEPTIDE SEQUENCES FROM LAWSONIA INTRACELLULARIS AND METHOD OF USE
US20050069572A1 (en) 2002-10-09 2005-03-31 Jennifer Elisseeff Multi-layered polymerizing hydrogels for tissue regeneration
FR2846659B1 (fr) 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
WO2004045542A2 (en) 2002-11-15 2004-06-03 Arizona Board Of Regents Arizona State University Therapeutic bioconjugates
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
EA010945B1 (ru) 2003-10-28 2008-12-30 Орган Тиссю Реженерасьон Репарасьон Рамплясман - Отр3 Применение биосовместимого полимера для изготовления медицинского устройства
WO2005055800A2 (en) 2003-12-15 2005-06-23 Technion Research & Development Foundation Ltd. Therapeutic drug-eluting endoluminal covering
US7842667B2 (en) 2003-12-22 2010-11-30 Regentis Biomaterials Ltd. Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same
EP2289567A3 (en) 2003-12-22 2011-06-22 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US7709439B2 (en) 2004-02-20 2010-05-04 Boston Scientific Scimed, Inc. Biomaterials for enhanced healing
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
JP2008503205A (ja) 2004-05-31 2008-02-07 ナショナル ユニヴァーシティ オブ シンガポール デコリンロイシンリッチリピート由来のペプチドおよびその使用
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
WO2006036681A2 (en) 2004-09-22 2006-04-06 Cartilix, Inc. Cartilage filling device
EP1804844A4 (en) 2004-09-29 2012-02-29 Univ Singapore COMPOSITE, PROCESS FOR ITS MANUFACTURE AND ITS APPLICATIONS
US20060241022A1 (en) 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates
WO2006047758A1 (en) 2004-10-27 2006-05-04 Massachusetts Institute Of Technology Novel technique to fabricate molded structures having a patterned porosity
US8283414B2 (en) 2004-11-23 2012-10-09 The Johns Hopkins University Compositions comprising modified collagen and uses therefor
WO2006089119A2 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Biological adhesive
WO2006089167A1 (en) 2005-02-18 2006-08-24 Cartilix, Inc. Glucosamine materials
CA2598251A1 (en) 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
GB2424223C (en) 2005-03-07 2011-02-02 Massachusetts Inst Technology Biomaterial.
EP1863404A2 (en) 2005-03-30 2007-12-12 Cartilix, Inc. Coated medical device
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US7737131B2 (en) 2005-03-31 2010-06-15 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US8415325B2 (en) 2005-03-31 2013-04-09 University Of Delaware Cell-mediated delivery and targeted erosion of noncovalently crosslinked hydrogels
US8367639B2 (en) 2005-03-31 2013-02-05 University Of Delaware Hydrogels with covalent and noncovalent crosslinks
US8338390B2 (en) 2005-03-31 2012-12-25 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
US20080069774A1 (en) 2005-11-17 2008-03-20 Lance Liotta Proteomic antisense molecular shield and targeting
US20070298071A1 (en) 2006-03-07 2007-12-27 Harley Brendan A Bioactive scaffold for therapeutic and adhesion prevention applications
US20070212385A1 (en) 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
CA2645324A1 (en) 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
AU2007299219A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20090162436A1 (en) 2006-06-14 2009-06-25 Carson Daniel D Compositions and methods for repair of tissues
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
US8114835B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles for tissue engineering
US8114834B2 (en) 2006-11-09 2012-02-14 Northwestern University Self-assembling peptide amphiphiles
WO2008066816A2 (en) 2006-11-28 2008-06-05 The Board Of Trustees Of The University Of Illinois Derivatization or ligaton of peptides
WO2008070179A2 (en) 2006-12-06 2008-06-12 Monsanto Technology, Llc Genes and uses for plant improvement
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
ES2596707T3 (es) 2007-04-16 2017-01-11 Regentis Biomaterials Ltd. Composiciones y métodos para la formación de armazones
WO2008146956A1 (en) 2007-05-06 2008-12-04 Byoung-Hyun Min Therapeutic composite for cartilage disorder using extracellular matrix (ecm) scaffold
WO2008152639A2 (en) 2007-06-12 2008-12-18 Bypass, Inc. Pressure pulse actuating device for delivery systems
US20090075281A1 (en) 2007-07-10 2009-03-19 Regents Of The University Of California Mtbe genes
US7993679B2 (en) 2007-09-25 2011-08-09 Integra Lifesciences Corporation Flowable wound matrix and its preparation and use
WO2009048280A2 (en) 2007-10-09 2009-04-16 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
MX2010010904A (es) 2008-04-04 2010-11-04 Univ Utah Res Found Eteres de glicosaminoglicosano semisinteticos alquilados, y metodos para elaborarlos y usarlos.
US20100004196A1 (en) 2008-06-17 2010-01-07 Hopitaux Universitaires De Geneve Heparan sulfate proteoglycan composition and use thereof
WO2010011857A2 (en) 2008-07-23 2010-01-28 The Johns Hopkins University Parenteral administration of a glucosamine
US20110269208A1 (en) 2008-08-15 2011-11-03 The Trustees Of The University Of Pennsylvania Cross-linked polymer network formed by sequential cross-linking
CN102216460A (zh) 2008-09-17 2011-10-12 希尔雷斯股份有限公司 生物量增加的转基因植物
FR2936247B1 (fr) 2008-09-24 2010-10-22 Ct Hospitalier Universitaire De Dijon Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire.
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
WO2010060485A1 (de) 2008-11-28 2010-06-03 Zetascience Gmbh Bioaktives hydrogel
KR101062068B1 (ko) 2008-12-01 2011-09-02 포항공과대학교 산학협력단 유착방지용 조성물
IL195764A0 (en) 2008-12-07 2009-11-18 Technion Res & Dev Foundation Compositions and methods for drug delivery
WO2010083179A2 (en) 2009-01-16 2010-07-22 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
NZ595310A (en) 2009-03-30 2013-05-31 Nestec Sa Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis; vimentin fragments
US20110182862A1 (en) 2009-04-03 2011-07-28 Green Wayne A Endophytic fungus and uses therefor
WO2010120830A1 (en) 2009-04-13 2010-10-21 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
FI20095452A0 (fi) 2009-04-23 2009-04-23 Suomen Punainen Risti Veripalv Uudet haaraiset sokerianalyysit
WO2010129547A1 (en) 2009-05-04 2010-11-11 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US20130052155A1 (en) 2009-11-09 2013-02-28 Drexel University Compositions and Methods for Treating a Disorder or Defect in Soft Tissue
MX2012005973A (es) 2009-12-04 2012-06-25 Euclid Systems Corp Composicion y metodos para la prevencion y tratamiento de degeneracion macular, retinopatia diabetica, y edema macular diabetico.
DK2513294T3 (en) 2009-12-16 2016-06-06 Regentis Biomaterials Ltd SKELETS FOR POLYMER-PROTEIN CONJUGATES, PROCEDURES FOR GENERATION THEREOF AND APPLICATIONS THEREOF
EP2528437A4 (en) 2010-01-26 2013-10-02 Univ Utah Res Found METHOD FOR TREATING OR PREVENTING CANCER EXPLOITATION BY MEANS OF SEMISYNTHETIC GLYCOSAMINOGLYCOSAN ETHER
EP2538957B1 (en) 2010-02-26 2019-07-24 Vascular Biosciences, Inc. Car peptide for homing, diagnosis,&targeted therapy for pulmonary and fibrotic disorders
US20130190246A1 (en) 2010-06-23 2013-07-25 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for use in vascular intervention
US9173919B2 (en) 2011-02-16 2015-11-03 Purdue Research Foundation Collagen-targeted nanoparticles
WO2012149515A2 (en) 2011-04-29 2012-11-01 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
US9217016B2 (en) 2011-05-24 2015-12-22 Symic Ip, Llc Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS COMPRISING HYALURONIC ACID-BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMER MOLECULES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS
US9540428B2 (en) 2012-07-03 2017-01-10 Ecole Polytechnique Federale De Lausanne (Epfl) Extracellular matrix heparin-binding domains
US9827321B2 (en) 2012-08-14 2017-11-28 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
WO2014038866A1 (ko) 2012-09-05 2014-03-13 아주대학교산학협력단 연골세포 유래 세포외 기질막을 이용한 신생혈관질환 치료용 조성물 및 각막 또는 결막 이식재
DE102012108560B4 (de) 2012-09-13 2018-12-20 Leibniz-Institut Für Polymerforschung Dresden E.V. Nichtkovalente selbstorganisierende Hydrogelmatrix für biotechnologische Anwendungen
WO2014063102A1 (en) 2012-10-19 2014-04-24 Cornell University Biomimetic boundary lubricants for articular cartilage
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
UY35195A (es) 2012-12-18 2014-07-31 Novartis Ag Composiciones y metodos para proteinas de accion prolongada
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
WO2014171084A1 (ja) 2013-04-16 2014-10-23 パナソニックＩｐマネジメント株式会社 電力変換装置、電力変換方法、モータシステム、３相モータ
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CA2956137A1 (en) 2014-05-12 2015-11-19 Alyssa Panitch Selectin and icam/vcam peptide ligand conjugates
WO2016061147A1 (en) 2014-10-13 2016-04-21 John Eric Paderi Luminal vessel coating for arteriovenous fistula
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
WO2016161333A2 (en) 2015-04-01 2016-10-06 Purdue Research Foundation Compositions comprising bioconjugates
US20160331841A1 (en) 2015-04-17 2016-11-17 Symic Ip, Llc Bioconjugates and uses thereof
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Also Published As

Publication number Publication date
SG11201506966RA (en) 2015-10-29
EP2970509A1 (en) 2016-01-20
JP6603650B2 (ja) 2019-11-06
HK1220217A1 (zh) 2017-04-28
EP2970509B1 (en) 2020-05-13
US20160129076A1 (en) 2016-05-12
EA201591454A1 (ru) 2015-12-30
MX2015012608A (es) 2016-07-06
US20190022175A1 (en) 2019-01-24
AU2014233537A1 (en) 2015-09-10
US9872887B2 (en) 2018-01-23
IL241054A0 (en) 2015-11-30
US9200039B2 (en) 2015-12-01
CA2903450A1 (en) 2014-09-18
JP2016516065A (ja) 2016-06-02
KR20150130419A (ko) 2015-11-23
ZA201506391B (en) 2017-09-27
WO2014144969A1 (en) 2014-09-18
EP2970509A4 (en) 2016-11-02
US20140288002A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015022917A2 (pt) peptidoglicanos sintéticos componentes da matriz extracelular
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
FR3026281B1 (fr) Organe d'application comportant deux parties assemblees.
GT201300131A (es) Metodos de tratamiento de trastornos asociados con el fgf21
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
BR112014033116A2 (pt) anticorpos para tau
BR112015017818A2 (pt) heteropolioxometalatos
UY4290Q (es) Caja para envase
CO2017011295A2 (es) Piroglutamato de vortioxetina
BR112015031594A2 (pt) composição de polipropileno reforçada
WO2016161333A3 (en) Compositions comprising bioconjugates
EA201790410A1 (ru) Содержащая цинеол композиция для назального применения
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112015032110A2 (pt) composições de lágrima artificial
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
EA201791716A1 (ru) Фармацевтический состав
BR112018071710A2 (pt) auxiliar de aplicação para o tratamento de feridas
WO2012142256A3 (en) Modulators of mitochondrial protein import

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements